FERMENTALG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.602 EUR | -5.20% |
|
+18.04% | +99.34% |
| Apr. 12 | Fermentalg: transfer to Euronext Growth on April 16 | CF |
| Apr. 04 | Fermentalg SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +99.34% | 28.43M | - | ||
| +33.37% | 49.46B | B- | ||
| +1.55% | 42.58B | B | ||
| +49.11% | 42.49B | A | ||
| -4.22% | 29.09B | C | ||
| +11.57% | 26.61B | B- | ||
| -21.00% | 18.64B | B | ||
| +7.36% | 13.16B | B+ | ||
| +28.30% | 12.55B | C+ | ||
| +23.80% | 12.1B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ALGAE Stock
- Ratings Fermentalg